Trial intelligence / Profile preview

Dose-dense FEC followed by weekly paclitaxel in primary breast cancer

2010-020772-38Phase 2Active

Sponsor: Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
Start: Jul 2010
Modality: Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Countries: 1

Overview

Phase 2, open-label, single-arm trial of fluorouracil, epirubicin, cyclophosphamide, paclitaxel and filgrastim in breast cancer, sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoint: Feasibility of regimen. Started Jul 2010; status: active.

Drugs

fluorouracilepirubicincyclophosphamidepaclitaxelfilgrastim

Conditions

breast cancer

Beyond the preview

Go deeper on 2010-020772-38.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2010-020772-38.